Review





Similar Products

86
Sanying Ltd primary antibodies against cd36
Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
Primary Antibodies Against Cd36, supplied by Sanying Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against cd36/product/Sanying Ltd
Average 86 stars, based on 1 article reviews
primary antibodies against cd36 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

96
Proteintech primary antibodies include cd36
Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
Primary Antibodies Include Cd36, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies include cd36/product/Proteintech
Average 96 stars, based on 1 article reviews
primary antibodies include cd36 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
Proteintech primary antibodies against cd36
Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
Primary Antibodies Against Cd36, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against cd36/product/Proteintech
Average 96 stars, based on 1 article reviews
primary antibodies against cd36 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
Proteintech primary antibodies against rabbit anti cd36
Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
Primary Antibodies Against Rabbit Anti Cd36, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against rabbit anti cd36/product/Proteintech
Average 96 stars, based on 1 article reviews
primary antibodies against rabbit anti cd36 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology primary antibodies against cd36 sc-7309
Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
Primary Antibodies Against Cd36 Sc 7309, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against cd36 sc-7309/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
primary antibodies against cd36 sc-7309 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ABclonal Biotechnology primary antibodies against cd36
Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
Primary Antibodies Against Cd36, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against cd36/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
primary antibodies against cd36 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Proteintech primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin
Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
Primary Antibodies Against Fth, Gpx4, Cd36, Scara1, Lox 1, Abca1, Abcg1, Scarb1, And β Actin, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin/product/Proteintech
Average 90 stars, based on 1 article reviews
primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ABclonal Biotechnology primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin
Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
Primary Antibodies Against Fth, Gpx4, Cd36, Scara1, Lox 1, Abca1, Abcg1, Scarb1, And β Actin, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Detection of protein expression and functional verification of CD36 and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.

Journal: Frontiers in Immunology

Article Title: Prognostic integration of tumor microenvironment and parthanatos-related genes in gastric cancer: a machine learning-driven risk model and immune landscape profiling

doi: 10.3389/fimmu.2026.1636331

Figure Lengend Snippet: Detection of protein expression and functional verification of CD36 and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.

Article Snippet: Subsequently, primary antibodies against CD36 (18836-1-AP, Sanying, China) or KIT (AF6153, Affinity, USA) were added, and the sections were incubated overnight at 4°C followed by incubation with HRP-conjugated secondary antibody (K5007, Dako, Denmark) at 37 °C for 30 minutes.

Techniques: Expressing, Functional Assay, Immunohistochemical staining, Staining, Migration

Correlation analysis of CD36, KIT with TME and PA. (A) Detection of IFN-γ secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (B) Detection of TNF-α secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001.**** denotes P < 0.0001. (C) Detection of IL-10 secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors.** denotes P < 0.01. *** denotes P < 0.001. (D) Immunofluorescence staining results of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (E) Immunofluorescence staining results of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (F) Differential analysis of immunofluorescence optical density of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (G) Differential analysis of the ratio of nuclear to total immunofluorescence optical density of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors.**** denotes P < 0.0001.

Journal: Frontiers in Immunology

Article Title: Prognostic integration of tumor microenvironment and parthanatos-related genes in gastric cancer: a machine learning-driven risk model and immune landscape profiling

doi: 10.3389/fimmu.2026.1636331

Figure Lengend Snippet: Correlation analysis of CD36, KIT with TME and PA. (A) Detection of IFN-γ secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (B) Detection of TNF-α secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001.**** denotes P < 0.0001. (C) Detection of IL-10 secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors.** denotes P < 0.01. *** denotes P < 0.001. (D) Immunofluorescence staining results of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (E) Immunofluorescence staining results of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (F) Differential analysis of immunofluorescence optical density of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (G) Differential analysis of the ratio of nuclear to total immunofluorescence optical density of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors.**** denotes P < 0.0001.

Article Snippet: Subsequently, primary antibodies against CD36 (18836-1-AP, Sanying, China) or KIT (AF6153, Affinity, USA) were added, and the sections were incubated overnight at 4°C followed by incubation with HRP-conjugated secondary antibody (K5007, Dako, Denmark) at 37 °C for 30 minutes.

Techniques: Immunofluorescence, Staining